Lexeo Therapeutics share price logo

Lexeo Therapeutics Share Price

NASDAQ: LXEO

Small Cap

$5.17

(+-0.10%)

as on

Lexeo Therapeutics Stock Performance

as on September 13, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $4.9
    $5.25
    downward going graph

    5.22%

    Downside

    1.55%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.45
    $11.72
    downward going graph

    71.95%

    Downside

    126.69%

    Upside

    downward going graph

Lexeo Therapeutics share price movements today

Previous Close
$5.18
Open
$5.20
Volume
2.2M
Day's Low - High
$4.9 - $5.25
52 Week Low - High
$1.45 - $11.72

Lexeo Therapeutics Historical Returns

1 Month Return
+ 9.75 %
3 Month Return
+ 31.47 %
1 Year Return
-46.43 %
3 Year Return
0 %
5 Year Return
0 %

Lexeo Therapeutics Stock Fundamentals & Key Indicators

Check Lexeo Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$279.7M

EPS (TTM)

-2.1389

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-6.48

Industry PE ratio

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-122.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

7076123500.00%

Lexeo Therapeutics Stock Valuation

Track how Lexeo Therapeutics P/E has moved over time to understand its valuation trends.

Lexeo Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (0.00x)

September 15, 2025

Industry (0.00x)

September 15, 2025

Today (-6.48x)

September 15, 2025

Highest (-0.94x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -6.48x

Lexeo Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lexeo Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Lexeo Therapeutics image
Lexeo Therapeutics
BUY$279.7MNA-6.480.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$61.1B256.98%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$38.7BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$101.1B47.85%28.0731.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Lexeo Therapeutics Stock including INR - Dollar returns

The Lexeo Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

Lexeo Therapeutics investment value today

Current value as on today

₹58,603

Returns

₹41,397

(-41.4%)

Returns from Lexeo Therapeutics Stock

₹46,536 (-46.54%)

Dollar Returns*

₹5,139 (+5.14%)

Analyst Recommendation on Lexeo Therapeutics Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Lexeo Therapeutics. Average target price of $16.38

Lexeo Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Lexeo Therapeutics.

What analysts predicted

68.44%UPSIDE

Target Price

$16.38

Current Price

$5.17

Analyzed by

11 Analysts

Target

$16.38

Lexeo Therapeutics target price $16.38, a slight upside of 68.44% compared to current price of $5.17. According to 11 analysts rating.

Lexeo Therapeutics Stock's Interest Amongst Investors

Search interest for Lexeo Therapeutics Stock has increased by 5% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:5% versus previous 30 day period

Lexeo Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
-
-
-
-
1
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-19
-13
-20
-14
-23
-23
-31
-27
-33
-30
EBITDA
-18
-13
-19
-13
-21
-23
-28
-25
-32
-25
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-18
-13
-20
-14
-21
-21
-29
-25
-32
-26
Income Tax Expense
0
0
0
0
0
-
-
-
-
-
Net Income
-18
-13
-20
-14
-21
-21
-29
-25
-32
-26
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-1333.54%
0.00%
0.00%

Lexeo Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
0
1
0
-
-
Gross Profit
0
1
0
-1
-2
Operating Income
-4
-50
-60
-68
-105
EBITDA
-4
-50
-58
-66
-96
Interest Expense
0
-
0
0
0
Depreciation
-
0
1
1
2
Income Before Tax
-5
-50
-59
-66
-98
Income Tax Expense
0
0
0
0
-
Net Income
-5
-50
-59
-66
-98
Net Profit Margin
-993.83%
-3055.04%
-9063.76%
0.00%
0.00%

Lexeo Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-13
-20
-14
-21
-21
-29
-25
-32
-26
Operating Cash Flow
-13
-13
-13
-14
-20
-17
-28
-21
-27
Investing Cash Flow
0
0
0
0
0
0
-93
15
-39
Financing Cash Flow
0
3
100
88
0
0
0
0
72
Change in Cash
-16
-6
86
73
-20
-17
-122
-6
6

Lexeo Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-50
-59
-66
-98
Operating Cash Flow
-44
-54
-59
-81
Investing Cash Flow
0
0
0
-94
Financing Cash Flow
150
0
103
88
Change in Cash
106
-55
44
-86

Insights on Lexeo Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 37.0K → 1.94M (in $), with an average increase of 82.9% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -32.65M → -26.10M (in $), with an average increase of 25.1% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, LXEO stock has moved up by 68.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.6% return, outperforming this stock by 122.0%

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
OrganisationLexeo Therapeutics
Headquarters345 Park Avenue South, New York, NY, United States, 10010
CEOMr. R. Nolan Townsend
E-voting on sharesClick here to vote

Key Management of Lexeo Therapeutics

Name

Title

Dr. Jose Manuel Otero Ph.D.

Chief Technical Officer

Mr. Louis Tamayo

CFO & Principal Accounting Officer

Dr. Sandi See Tai M.D.

Chief Development Officer

Mr. R. Nolan Townsend

CEO & Director

Dr. Ronald G. Crystal M.D.

Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board

Ms. Jenny R. Robertson J.D.

Chief Legal Officer

Mr. Jordan M. Baumhardt Ph.D.

Vice President of Corporate Development

Ms. Leslie DiRisio

Senior Vice President of Development Operations

Mr. Ryan McHenry

VP & Corporate Controller

Dr. Eric Adler M.D.

Chief Medical Officer & Head of Research

FAQs

What is Lexeo Therapeutics share price today?

Lexeo Therapeutics share price today is $5.17 as on at the close of the market. Lexeo Therapeutics share today touched a day high of $5.25 and a low of $4.9.

What is the 52 week high and 52 week low for Lexeo Therapeutics share?

Lexeo Therapeutics share touched a 52 week high of $11.72 on and a 52 week low of $1.45 on . Lexeo Therapeutics stock price today i.e. is closed at $5.17,which is 55.89% down from its 52 week high and 256.55% up from its 52 week low.

What is Lexeo Therapeutics's market capitalisation today?

Lexeo Therapeutics market capitalisation is $0.00T as on .

How to invest in Lexeo Therapeutics Stock (LXEO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lexeo Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lexeo Therapeutics Shares that will get you 0.2901 shares as per Lexeo Therapeutics share price of $5.17 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Lexeo Therapeutics Stock (LXEO) from India?

Indian investors can start investing in Lexeo Therapeutics (LXEO) shares with as little as ₹88.27 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Lexeo Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Lexeo Therapeutics share’s latest price of $5.17 as on September 13, 2025 at 1:29 am IST, you will get 1.9342 shares of Lexeo Therapeutics. Learn more about fractional shares .